[Ip-health] Medicines Patent Pool Signs Agreement with Shilpa Medicare to Increase Generic Production

Kaitlin Mara kmara at medicinespatentpool.org
Mon Jun 24 15:02:27 PDT 2013

25 JUNE 2013: The Medicines Patent Pool, Shilpa Medicare, and Gilead
Sciences have signed an agreement to increase access to treatments for HIV.

The agreement will allow Shilpa Medicare to produce five key HIV medicines
for sale in 100 ­ 112 countries, depending on the medicine, and covering a
majority of people living with HIV.

“We are delighted to be working with the Medicines Patent Pool and Gilead
Sciences to speed the development of HIV treatments for people who need it
and have struggled to access it,” said Mr. Vishnukant Bhutada, Managing
Director of Shilpa Medicare. Reva Pharma, an associated company of Shilpa
Medicare will assist in marketing Shilpa’s ARV products including
coordinating with MPP and other stakeholders with regard to this therapy.

Shilpa is an active pharmaceutical ingredient (API) and dosage form
manufacturing company based in India that has decided to enter the field
of HIV medicines. Reva Pharma is a global pharmaceutical organisation that
operates in regulated and emerging markets.

Shilpa Medicare joins five other generic manufacturers who are currently
signed up to produce HIV medicines licensed to the MPP by Gilead Sciences
in July 2011, including two API manufacturers. Adding Shilpa to this group
will help ensure that the supply of key HIV medicines will grow to meet
rising demands for HIV treatment.

The medicines covered in this agreement are: tenofovir, emtricitabine,
cobicistat, elvitegravir and a combination of the four known as “the Quad.”

“We are excited to add Shilpa Medicare to our sub-­-licensees, who are
essential in working with us to achieve the aim of expanding access to
quality, effective HIV treatment in developing countries,” said Greg
Perry, Medicines Patent Pool Executive Director.

Under the agreement, Shilpa will also benefit from technology transfer to
aid generic manufacture of these medicines. The four-­medicines-in­-one
Quad received approval from the US Food and Drug Administration on 27
August 2012. The Quad is important as it simplifies treatment delivery,
which is particularly useful for people treating HIV in developing

More information about the Ip-health mailing list